Compare FEIM & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | PEPG |
|---|---|---|
| Founded | 1961 | 2018 |
| Country | United States | United States |
| Employees | N/A | 56 |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.3M | 425.1M |
| IPO Year | 1994 | 2022 |
| Metric | FEIM | PEPG |
|---|---|---|
| Price | $48.11 | $5.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $42.50 | $11.67 |
| AVG Volume (30 Days) | 149.6K | ★ 596.2K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.95 | 25.61 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $69,811,000.00 | N/A |
| Revenue This Year | $5.52 | N/A |
| Revenue Next Year | $17.07 | N/A |
| P/E Ratio | $186.64 | ★ N/A |
| Revenue Growth | ★ 26.30 | N/A |
| 52 Week Low | $14.41 | $0.89 |
| 52 Week High | $61.47 | $7.80 |
| Indicator | FEIM | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 44.06 |
| Support Level | $45.65 | $4.62 |
| Resistance Level | $59.91 | $5.50 |
| Average True Range (ATR) | 4.94 | 0.59 |
| MACD | -0.31 | -0.08 |
| Stochastic Oscillator | 20.41 | 21.07 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.